<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03208257</url>
  </required_header>
  <id_info>
    <org_study_id>1050522</org_study_id>
    <nct_id>NCT03208257</nct_id>
  </id_info>
  <brief_title>Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2</brief_title>
  <acronym>ECASSS-R2</acronym>
  <official_title>Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samuel Brown</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Intermountain Health Care, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a common syndrome caused by the body's response to an infection. Septic shock&#xD;
      is responsible for 10% of all ICU admissions and 30% of ICU deaths. Use of &quot;beta blocker&quot;&#xD;
      medications may improve outcomes after septic shock. This pilot study evaluates protocols to&#xD;
      infuse the beta blocker esmolol in patients with septic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single arm, feasibility study of esmolol infusion in septic shock. The&#xD;
      objective is to evaluate the feasibility, adequacy, and efficiency of study protocols for a&#xD;
      subsequent ECASSS study. This study (ECASSS-R2) extends observations made in an initial&#xD;
      pilot, ECASSS-R.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 7, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Organ-failure-free days</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause hospital mortality</measure>
    <time_frame>During hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause 28-day and 90-day mortality</measure>
    <time_frame>28 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak serum high-sensitivity troponin</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular (LV) longitudinal strain</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol hydrochloride infusion</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>BREVIBLOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Within 72 hours of admission to the ICU and septic shock (sepsis present at time of&#xD;
             admission)&#xD;
&#xD;
             a. Septic shock defined by SEPSIS-3 consensus criteria as i. Suspected or documented&#xD;
             infection ii. Sequential Organ Failure Assessment (SOFA) score increased by at least 2&#xD;
             points over baseline iii. Lactate &gt; 2mmol/L iv. Receiving vasopressors to treat&#xD;
             hypotension after at least 20 ml/kg intravenous crystalloid volume expansion&#xD;
&#xD;
          3. Receiving vasopressors through a central venous catheter for more than 60 minutes.&#xD;
&#xD;
          4. Arterial catheter in place or expected to be placed imminently.&#xD;
&#xD;
          5. Heart rate &gt; 90/min while receiving vasopressors for more than 60 minutes.&#xD;
&#xD;
          6. Adequately volume expanded, as manifest by any of the following, performed as part of&#xD;
             routine clinical care (i.e., no study procedures will be performed before signed&#xD;
             consent). If none of these measures are clinically available, the clinical attending&#xD;
             must confirm that volume expansion is adequate. (After enrollment, a final safety&#xD;
             check will confirm the adequacy of volume expansion.)&#xD;
&#xD;
               1. Central venous pressure (CVP) &gt; 15 mm Hg.&#xD;
&#xD;
               2. Negative Passive-Leg Raise (PLR) maneuver (&lt;10% increase in cardiac output after&#xD;
                  PLR).&#xD;
&#xD;
               3. No cardiac output response (&lt;10% increase) after rapid infusion (&lt;5 min) of 250&#xD;
                  ml of IV crystalloid (i.e., a graded volume expansion challenge [GVEC]).&#xD;
&#xD;
               4. Inferior vena cava (IVC) plethora&#xD;
&#xD;
               5. For patients who happen to be breathing passively (i.e., paralyzed or deeply&#xD;
                  sedated) on a positive pressure mechanical ventilator delivering at least 8 ml/kg&#xD;
                  tidal volumes and in normal sinus rhythm, stroke volume variability &lt;13% (such&#xD;
                  patients are acknowledged to be uncommon; the protocol does not recommend or&#xD;
                  require the induction of passive breathing).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of informed consent.&#xD;
&#xD;
          2. Currently receiving ExtraCorporeal Membrane Oxygenation (ECMO).&#xD;
&#xD;
          3. Known pregnancy or nursing.&#xD;
&#xD;
          4. Patient is a prisoner.&#xD;
&#xD;
          5. Patient on hospice (or equivalent comfort care approach) at or before the time of&#xD;
             enrollment.&#xD;
&#xD;
          6. Known or current atrial fibrillation.&#xD;
&#xD;
          7. Previously enrolled in the trial.&#xD;
&#xD;
          8. Known allergy to esmolol or vehicle (see Appendix 2 for BREVIBLOC vehicle&#xD;
             ingredients).&#xD;
&#xD;
          9. Receipt of nodal blocking agents (see Appendix 3 for list of such agents) within three&#xD;
             half lives&#xD;
&#xD;
         10. Hemoglobin &lt; 7 gm/dl.&#xD;
&#xD;
         11. Cardiac arrest within 24 hours.&#xD;
&#xD;
         12. Pulmonary hypertension (moderate or severe), from documented history of prior right&#xD;
             heart catheterization or current evidence on transthoracic echocardiogram (TTE) of any&#xD;
             of the following&#xD;
&#xD;
               -  Mean Pulmonary Arterial Pressure (mPAP) ≥ 35mmHg (millimeters of mercury)&#xD;
&#xD;
               -  Systolic Pulmonary Arterial Pressure (SPAP) ≥ 60mmHg (millimeters of mercury)&#xD;
&#xD;
         13. Cardiovascular collapse, as manifested by inability to achieve a mean arterial&#xD;
             pressure (MAP) of 65 mmHg with vasopressor therapy.&#xD;
&#xD;
         14. Cardiogenic shock, as defined by any of the following&#xD;
&#xD;
               -  Cardiac index ≤ 2.3 L/min/m2&#xD;
&#xD;
               -  Ejection fraction ≤ 30%&#xD;
&#xD;
               -  ScvO2 ≤ 60%&#xD;
&#xD;
               -  Current infusion of any dose of dobutamine, milrinone, or dopamine (if dopamine&#xD;
                  is being used for clinically diagnosed bradycardia or cardiogenic shock)&#xD;
&#xD;
               -  Current infusion of epinephrine for clinically diagnosed cardiogenic shock&#xD;
&#xD;
         15. Significant atrioventricular dysfunction&#xD;
&#xD;
               -  Sick sinus syndrome&#xD;
&#xD;
               -  PR interval &gt; 200 msec&#xD;
&#xD;
               -  Current evidence or prior history of Grade 2 or Grade 3 heart block&#xD;
&#xD;
               -  Pacemaker or plans to place a pacemaker&#xD;
&#xD;
         16. Pheochromocytoma or status asthmaticus&#xD;
&#xD;
         17. Receiving clonidine, guanfacine, or moxonidine&#xD;
&#xD;
         18. Worse than moderate aortic stenosis&#xD;
&#xD;
               -  Known aortic stenosis, with any of (1) mean gradient ≥ 40 mmHg OR (2) maximum&#xD;
                  gradient ≥ 60mmHg OR (3) aortic valve area ≤ 1.0cm2 OR (4) aortic valve area&#xD;
                  index ≤ 0.85cm2/m2 body surface area.&#xD;
&#xD;
         19. Worse than mild mitral stenosis&#xD;
&#xD;
               -  Known mitral stenosis, with any of (1) valve area ≤ 1.5 cm2 OR mean gradient ≥ 5&#xD;
                  mmHg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel M Brown, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Intermountain Health Care, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie T Aston, MBA</last_name>
    <phone>(801) 507-4606</phone>
    <email>valerie.aston@imail.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David P Tomer, MS</last_name>
    <phone>(801) 507-4694</phone>
    <email>David.Tomer@imail.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie T Aston, MBA</last_name>
      <phone>801-507-4606</phone>
      <email>valerie.aston@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>David P Tomer, MS</last_name>
      <phone>(801) 507-4694</phone>
      <email>David.Tomer@imail.org</email>
    </contact_backup>
    <investigator>
      <last_name>Samuel M Brown, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colin K Grissom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael J Lanspa, MD MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emily Wilson, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ithan Peltan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellie Hirshberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Crossno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivian Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah Beesley, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Burk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>July 2, 2017</study_first_submitted>
  <study_first_submitted_qc>July 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2017</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Intermountain Health Care, Inc.</investigator_affiliation>
    <investigator_full_name>Samuel Brown</investigator_full_name>
    <investigator_title>Associate Professor, Pulmonary and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>esmolol</keyword>
  <keyword>adrenergic storm</keyword>
  <keyword>septic shock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In order to protect patient privacy and comply with relevant regulations, identified data will be unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

